Snapshot img

Bio-pharma Market Size 2024-2028

The bio-pharma market size is forecast to increase by USD 204.09 billion at a CAGR of 7.98% between 2023 and 2028.

The market is experiencing significant growth driven by the increasing prevalence of health disorders and the rise in the production of vaccines. The global population is aging, leading to an increase in chronic diseases such as cancer, type 2 diabetes, and cardiovascular diseases. This trend is particularly prominent in developed markets like the US, where an aging population and rising healthcare costs are fueling demand for innovative and effective bio-pharmaceutical solutions. Another key driver for the market is the production of vaccines, which has gained significant momentum in recent years due to the ongoing COVID-19 pandemic.
The rapid development and distribution of vaccines have highlighted the critical role of the bio-pharma industry in addressing global health crises. However, the high cost of bio-pharmaceuticals remains a significant challenge for market growth. This issue is compounded by regulatory requirements and lengthy approval processes, which can delay the entry of new products and limit competition. To capitalize on market opportunities and navigate challenges effectively, companies in the market must focus on innovation, cost reduction, and regulatory compliance. Strategic partnerships, collaborations, and acquisitions can help companies leverage each other's strengths and resources to bring new products to market more quickly and cost-effectively.

What will be the Size of the Bio-pharma Market during the forecast period?

Request Free Sample

The market encompasses a diverse range of therapeutic modalities, including monoclonal antibodies, recombinant growth factors, purified proteins, recombinant enzymes, vaccines, recombinant hormones, cell therapies, gene therapies, synthetic immunomodulators, and various other living organisms derived from bacteria, yeast, and mammalian cells. Biotechnological processes are employed to produce these complex molecules, which target specific biological pathways, receptors, and molecular structures. Biopharmaceuticals address a broad spectrum of diseases, such as cancer, diabetes, psoriasis, rheumatoid arthritis, genetic mutations, and various other conditions.
Personalized medicine and the identification of biomarkers have significantly influenced the market's growth trajectory. The market's size and direction reflect the ongoing advancements in technology and the increasing demand for innovative therapeutic solutions.

How is the Bio-pharma Industry segmented?

The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Monoclonal antibodies
  Recombinant growth factors
  Vaccines
  Recombinant hormones
  Others


Application

  Oncology
  Autoimmune disorder
  Metabolic disorder
  Hormonal disorder
  Others


Geography

  North America

    US


  Europe

    France
    Germany


  Asia
  Rest of World (ROW)

By Product Insights

The monoclonal antibodies segment is estimated to witness significant growth during the forecast period. Monoclonal antibodies represent a significant segment of the market due to their high price point and life-saving capabilities, despite lower sales volumes compared to other pharmaceuticals. Revenues from monoclonal antibodies are substantial, making them a valuable contribution to the industry. The monoclonal antibodies segment is projected to grow during the forecast period, with companies investing heavily in research and development (R&D) of biologic drugs. Monoclonal antibodies hold the largest share in this area, as companies focus on expanding their bio-pharmaceutical domains.

Key therapeutic areas for monoclonal antibodies include oncology, autoimmune disorders, metabolic disorders, hormonal disorders, cardiovascular diseases, neurological diseases, and chronic conditions such as dementia and Alzheimer's disease. Technologies such as high throughput screening, combinatorial chemistry, computational modeling, genomics, next-generation sequencing, gene editing techniques, and purified proteins are essential in the development and production of monoclonal antibodies and other biopharmaceuticals.

Get a glance at the market report of share of various segments Request Free Sample

The Monoclonal antibodies segment was valued at USD 151.68 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights

This statistic displays the compound annual growth rate (CAGR) of European biotechnology companies' market capitalization between 2012 and 2016. During this period, Irish company Jazz Pharmaceuticals had a CAGR of 42 percent.

Snapshot img

Biotech Market Size 2025-2029

The biotech market size is forecast to increase by USD 805.6 billion at a CAGR of 12.4% between 2024 and 2029.

The market is experiencing significant growth, driven by the increasing innovation and investment from market companies. These companies are expanding their research and development efforts to bring new products and technologies to market, addressing unmet medical needs and advancing scientific discoveries. However, this growth comes with challenges, primarily regulatory compliance. Stringent regulations governing the biotech industry ensure the safety and efficacy of products, but they also add costs and complexity to the development process. Biologics, comprised of monoclonal antibodies, vaccines, recombinant proteins, and cell and gene therapies, are derived from living organisms and cater to the treatment of numerous diseases, such as cancer, autoimmune disorders, and genetic conditions. Navigating these regulations requires the regulatory landscape and strategic planning.
For companies seeking to capitalize on market opportunities and navigate challenges effectively, it is essential to stay informed of the latest regulatory trends and best practices. Additionally, collaboration with regulatory agencies and industry experts can help streamline the development process and bring products to market more efficiently. Overall, the market presents significant opportunities for growth, but companies must be prepared to navigate regulatory complexities and invest in innovation to stay competitive.

What will be the Size of the Biotech Market during the forecast period?

Request Free Sample

The market encompasses a dynamic and innovative industry focused on advancing biological systems through engineering, gene therapies, and tissue culturing. This sector is driving progress in various areas, including medicine, environmental sustainability, and agriculture. Notable applications include the development of treatments for conditions such as HIV, diabetes, obesity, neurological disorders, and transfyretin amyloidosis. Significant investments continue to fuel market growth, with innovative companies spearheading clinical success in areas like personalized medicine and regeneration technologies. Biotech is also making strides in the production of genetically modified crops, leading to improved plant varieties and increased agricultural efficiency. Government support and approval processes are crucial components of the market's growth trajectory.
Technological advancements, such as molecular breeding and cloning, are revolutionizing the way we approach challenges in healthcare and agriculture. The biotech industry's positive outcomes extend beyond the conventional plan, with potential solutions for societal issues like malaria and sedentary lifestyle-related diseases. Market revenue is expected to grow substantially as biotech continues to deliver breakthroughs in medicine, bio-pharmaceuticals, and bio-agriculture. The future of this sector is bright, as it continues to push the boundaries of science and technology to address some of the world's most pressing challenges.

How is this Biotech Industry segmented?

The biotech industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Biologics
  Therapeutics
  Diagnostics
  Industrial biotechnology
  Others


Type

  Red biotechnology
  White biotechnology
  Green biotechnology
  Grey biotechnology
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Sweden
    Switzerland
    UK


  Asia
  Rest of World (ROW)

By Product Insights

The biologics segment is estimated to witness significant growth during the forecast period. The market encompasses a range of product categories, with biologics emerging as a key and expanding segment. In August 2023, Novartis finalized its acquisition of Chinook Therapeutics, Inc., a Seattle, WA-based biopharmaceutical company specializing in precision medicines for kidney diseases. Valued at up to USD 3.5 billion, this acquisition underscores the strategic significance of biologics within the global biotech sector. Biotechnology advancements in areas like gene editing, proteomics, and genomics continue to fuel innovation in disease treatment and prevention.

Biotech startups and established biopharma companies alike invest heavily in research and development, driving medical breakthroughs and healthcare solutions. The biotech industry's focus on patient care, disease management, and pharmaceutical innovation is transforming healthcare trends and improving health outcomes. Biotechnology education, policy, and regulation play crucial roles in fostering a sustainable and ethical industry.

Ge

As of 2024, 125 pharmaceutical and biotechnological companies were among the leading 800 companies in the European Union. France had the highest number of leading pharmaceutical and biotechnological companies in that year, with 29 companies listed. Leading markets Despite not having the highest amount of leading pharma companies in Europe, Germany was the leading pharmaceutical market in Europe, with total revenues of some 69 billion euros in 2023. France and Italy followed with revenues of around 46 billion and 41 billion euros, respectively. The United Kingdom and Spain are the next big European markets. Development in pharmaceuticals in Europe In 2023, nearly 2,800 pharmaceutical patents were granted by the European Patent Office. Interestingly, the country with the highest number of European pharmaceutical patents granted was the United States at 957, followed by 231 patents granted to Japanese companies.

The Report Covers Global Biopharmaceuticals Market Size, Segmentation & Growth and is Segmented by Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Vaccines, Recombinant Enzymes, Cell, Gene Therapies, Cytokines, Interferons, and Interleukins, and Other Product Types), Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases, Neurological Diseases, and Other Diseases), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The Report Offers the Value in (USD) for the Above Segments.

The global biopharmaceuticals excipients market is experiencing robust growth, driven by the increasing demand for biopharmaceuticals and advancements in drug delivery systems. While the exact market size for 2025 isn't provided, considering a plausible CAGR (let's assume a conservative 7% based on industry reports for similar sectors) and a hypothetical 2019 market size of $15 billion (a reasonable estimate given the significant size of the pharmaceutical industry), the market size in 2025 could be estimated at approximately $22 billion. This growth is projected to continue, with a sustained CAGR throughout the forecast period (2025-2033). Key drivers include the rising prevalence of chronic diseases necessitating increased pharmaceutical consumption, the growing adoption of advanced drug delivery technologies like injectables and targeted therapies, and ongoing research and development in innovative excipients enhancing drug efficacy and stability. The market is segmented by type (including triglycerides, mannitol, sorbitol, sucrose, dextrose, starch, and others) and application (oral, topical, and parenteral formulations). The diverse applications underscore the versatility of excipients in modern drug manufacturing. Major players such as Dow, BASF, and Roquette are actively contributing to market expansion through their R&D investments and geographical expansions. The market's growth trajectory is influenced by several factors. Ongoing regulatory approvals for novel drugs and excipients contribute significantly. However, challenges remain. Price fluctuations of raw materials, stringent regulatory hurdles for excipient approvals, and the rising costs associated with research and development present restraints to market growth. Despite these challenges, the long-term outlook for the biopharmaceuticals excipients market remains optimistic, fueled by the continued growth of the biopharmaceutical industry and the increasing importance of excipients in optimizing drug performance and patient outcomes. The geographical distribution of the market is broad, with North America and Europe currently holding significant shares, but growth opportunities exist in emerging markets like Asia-Pacific and other regions. This comprehensive report provides a detailed analysis of the global biopharmaceuticals excipients market, projected to reach $15 billion by 2028. It offers invaluable insights into market dynamics, growth drivers, challenges, and key players, equipping stakeholders with the knowledge necessary to navigate this rapidly evolving landscape. Keywords: Biopharmaceuticals Excipients Market, Pharmaceutical Excipients, Drug Delivery Systems, Market Size, Market Share, Market Trends, Market Analysis, Market Research, Biopharmaceutical Manufacturing, Excipient Suppliers.

Swiss companies Roche and Novartis held the second and third place among European pharma and biotech companies, accumulating a market capitalization of approximately 255 billion U.S. dollars, each. This statistic shows the leading pharmaceutical and biotechnology companies from Europe as of September 2024, based on market capitalization.

Europe Biopharmaceutical Processing Equipment and Consumables Market by Product Type {Filtration, Chromatography [Consumables, Equipment], Disposable Bioreactors, Cell Culture Media, Shakers, Services), Application (Vaccine, mAb, R&D), and End User - Forecast to 2032

The European Pharmaceutical Market Report Covers Pharma Logistics Companies and is Segmented by Product (Generic Drugs and Branded Drugs), Operation (Cold Chain Transport and Non-Cold Chain Transport), Application (Biopharma and Chemical Pharma), Transport (Airways, Railways, Roadways, and Seaways), and Geography (Germany, The United Kingdom, The Netherlands, France, Italy, Spain, Poland, Belgium, Sweden, and the Rest of Europe). The Report Offers the Market Sizes in Value Terms (USD) for all the Above Segments.

This data package consists of bioresearch monitoring information system (BMIS) dataset, directory of the different biotech and biopharmaceutical and pharmaceutical companies in the United States and the European Union, establishment registration database, drug wholesale distributor and third-party logistics provider reporting database, establishment inspections conducted by FDA, and FDA post-marketing requirements and commitments searchable database.

US And Europe Ethanol And Specialty Chemicals In Pharmaceutical Manufacturing Market size was valued at USD 16,940.49 Million in 2023 and is projected to reach USD 22,181.23 Million by 2031, growing at a CAGR of 3.93% from 2024 to 2031.

US And Europe Ethanol And Specialty Chemicals In Pharmaceutical Manufacturing Market Overview

Significant driver is the rising prevalence of biopharmaceuticals and biologics, which require intricate and sensitive manufacturing processes. Ethanol plays an essential role as a solvent, while various specialty chemicals are critical for purification, extraction, and stabilization processes. With increased investments in biotechnology and bio-based products, particularly within the EU, manufacturers are expanding biopharmaceutical production capabilities. For example, Circular Bio-Based Europe (CBBE) has announced a total funding of €213 million (USD 232.08 million) aimed at fostering competitive, circular bio-based industries across Europe.

The size and share of the market is categorized based on Application (Immunology, Endocrinology, Others) and Product (Biologics, Biosimilars) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

Germany was the leading pharmaceutical market in Europe with a total revenue of nearly 69 billion euros in 2023. France and Italy followed with revenues of 46.5 billion and 40.7 billion euros respectively. The top five were rounded off by Spain and Poland. German pharmaceutical marketWhen the revenue of the German pharmacy market is broken down, it is prescription drugs that account for the majority of the revenues. Prescription medication accounted for around 39 billion euros of revenue, followed by pharmacy-only drugs at some 3.5 billion euros. German pharmaceutical exportsOver a 13-year period, the value of pharmaceutical exports from Germany has skyrocketed. Increasing from approximately 18.8 billion euros in 2000 to some 113 billion euros in 2023. The leading destination for these exports is the United States, followed by the Netherlands and Switzerland.

The U.S. And Europe Pharmaceutical Manufacturing Market size was valued at USD 412.50 billion in 2023 and is projected to reach USD 654.20 billion by 2032, exhibiting a CAGR of 6.81 % during the forecasts period. The scope of the U. S. and Europe pharmaceutical manufacturing market includes the manufacturing and creating of the medications as well as the pharmaceutical products. This market comprises activities such as formulation of drugs, manufacturing of the drug, testing and certification of the quality, and placing the drug in the appropriate packaging. Some of the uses include formulating prescription medicines, over the counter drugs, and biopharmaceuticals. Such impacts include; growing enrolment of patients on new techniques, rising incidences of persistent diseases and development of technologies in the production of the equipment. Trends include the transformation from a disease-centered approach to a patient-centered one, the continued rise in the polygenic biological medicines and biological generics, integration of innovative practices of manufacturing like continuous processing and automation, and the need to observe regulatory requirements to satisfy the strict standards of the two regions.

The size and share of the market is categorized based on Type (Antiparasitic, Biological Products, Antibacterial, Others) and Application (Prevention, Treatment) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

Europe Pharmaceutical Packaging Market size was valued at USD 6.22 Billion in 2024 and is projected to reach USD 48.03 Billion by 2032, growing at a CAGR of 32.12% from 2026 to 2032.

Key Market Drivers

Aging Population and Increased Medication Consumption: According to Eurostat, the EU’s population aged 65 and older is predicted to grow to 130.2 million by 2050, accounting for 30.3% of the total population, up from 90.5 million (20.3%) in 2019. The European Medicines Agency (EMA) reports that this demographic shift has led to a 42% increase in prescription medication usage between 2018-2023, with the average elderly person in Europe consuming 3.6 prescription medications per day, driving demand for specialized pharmaceutical packaging solutions.

Growth in Biologic Drugs and Cold Chain Packaging: The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that biologics accounted for 34% of all new medicine approvals in Europe by 2023, up from 22% in 2018.

The market size of the Lyophilization Services For Biopharmaceuticals Market is categorized based on Application (Pharmaceutical & Biotechnology Companies, Research Institutes, Others) and Product (Product & Cycle Development, Clinical Manufacturing, Commercial Manufacturing, Freeze Drying Analytical Services) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

This report provides insights into the market size and forecasts the value of the market, expressed in USD million, across these defined segments.

The market size of the Single Use Technologies For Biopharmaceuticals Market is categorized based on Type (Single-use Bioreactors, Membrane Adsorbers, Media Bags, Bioprocess Containers, Others) and Application (Contract Manufacturing Organizations, Biopharmaceutical Manufacturers) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

This report provides insights into the market size and forecasts the value of the market, expressed in USD million, across these defined segments.

Europe's Healthcare Cold Chain Logistics Market Rport is Segmented by Product (biopharmaceuticals, Vaccines, And Clinical Trial Materials), Services (transportation, Storage, Packaging, And Value-Added Services (packaging and Labeling), End User (hospitals, Clinics, And Pharmaceuticals, Biopharmaceutical, And Biotechnology) and Country (Germany, France, Italy, Spain, And Rest of Europe). The Report Offers Market Size and Forecasts for the European Healthcare Cold Chain Logistics Market in Value (USD) for all the Above Segments.

The size and share of the market is categorized based on Application (Liquid Cancers, Solid Cancers) and Product (Biologics, Biosimilars) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).